Generic Name and Formulations:
Norgestimate 0.25mg, ethinyl estradiol 35micrograms (21 tabs); inert (7 tabs).
Indications for MONONESSA:
1 tab daily for 28 days; repeat.
Thrombophlebitis or thromboembolic disorders. Cerebral vascular or coronary artery disease. Breast or other estrogen-dependent neoplasms. Undiagnosed abnormal genital bleeding. Cholestatic jaundice of pregnancy or jaundice with prior OC use. Hepatic adenoma or carcinoma. Pregnancy (Cat.X).
Smokers over 35 years of age: not recommended. Uncontrolled hypertension. Hypertriglyceridemia. Discontinue if jaundice, visual disturbances, migraine or other severe headaches occur. Do regular complete physical exams. May need barrier contraception with Sunday starts or postpartum use (see literature). Nursing mothers: not recommended.
Progestin + estrogen.
Antagonized by hepatic enzyme inducing drugs (eg, rifampin, griseofulvin, St. John's wort), possibly others. May affect measurement of sex hormone-binding globulin levels.
Hypertension, nausea, vomiting, breakthrough bleeding, amenorrhea, transient delay of ovulation after discontinuation, edema, chloasma, mastodynia, headache, intolerance to contact lenses. Increased risk of gallbladder disease, thromboembolic disorders.
Endocrinology Advisor Articles
- Behavioral Weight Loss Interventions May Prevent Obesity
- Executive Function Predicts T1D Management Into Emerging Adulthood
- Association Between Urine Complement Proteins and Kidney Disease, Mortality in T2D
- Intensive Blood Pressure Therapy Lowers Cardiovascular Risk in Diabetes
- Rates of Incident Type 2 Diabetes in Chronic Kidney Disease
- Bioethics Concerns Should Be a Key Element in mHealth Technology Development
- Gestational Diabetes Associated With Increased Risk for Postpartum Depression
- High Prevalence of Obstructive Sleep Apnea Syndrome May Favor Screening in Diabetes
- Update on the T2D-Dementia Link: Interview With Experts
- Dozens of Medical Groups Join Forces to Improve Diagnoses